7.49
price down icon4.59%   -0.36
after-market After Hours: 7.49
loading
Zevra Therapeutics Inc stock is traded at $7.49, with a volume of 431.81K. It is down -4.59% in the last 24 hours and down -6.49% over the past month.
See More
Previous Close:
$7.85
Open:
$7.71
24h Volume:
431.81K
Relative Volume:
1.04
Market Cap:
$444.29M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-5.8062
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
-8.77%
1M Performance:
-6.49%
6M Performance:
+7.93%
1Y Performance:
+29.14%
1-Day Range:
Value
$7.45
$7.745
1-Week Range:
Value
$7.45
$8.22
52-Week Range:
Value
$4.20
$9.76

Zevra Therapeutics Inc Stock (ZVRA) Company Profile

Name
Name
Zevra Therapeutics Inc
Name
Phone
(321) 939-3416
Name
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2025-03-11
Name
Latest SEC Filings
Name
ZVRA's Discussions on Twitter

Compare ZVRA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ZVRA
Zevra Therapeutics Inc
7.49 444.29M 27.46M -46.05M -33.83M -1.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-08-25 Resumed Cantor Fitzgerald Overweight
Oct-07-24 Initiated Guggenheim Buy
Sep-24-24 Initiated JMP Securities Mkt Outperform
Sep-24-24 Reiterated Maxim Group Buy
Apr-02-24 Reiterated Maxim Group Buy
Mar-12-24 Initiated William Blair Outperform
Mar-17-23 Initiated Maxim Group Buy
View All

Zevra Therapeutics Inc Stock (ZVRA) Latest News

pulisher
08:21 AM

Zevra therapeutics director Corey Watton buys $2,351 in stock - Investing.com India

08:21 AM
pulisher
05:24 AM

Zevra Therapeutics Asks Shareholders to Reject Director Nominees by Activist Investor - MarketScreener

05:24 AM
pulisher
04:33 AM

Zevra Therapeutics Files Preliminary Proxy - The Manila Times

04:33 AM
pulisher
04:12 AM

Proxy Fight Erupts at Zevra: Former CEO Challenges $150M Cash-Rich Biotech - Stock Titan

04:12 AM
pulisher
Mar 26, 2025

Trend Tracker for (ZVRA) - news.stocktradersdaily.com

Mar 26, 2025
pulisher
Mar 23, 2025

John Bode Bought 33% More Shares In Zevra Therapeutics - simplywall.st

Mar 23, 2025
pulisher
Mar 23, 2025

Zevra Therapeutics Independent Director Acquires 33% More Stock - Yahoo Finance

Mar 23, 2025
pulisher
Mar 22, 2025

Insider Buying: John Bode Acquires Additional Shares of Zevra Th - GuruFocus

Mar 22, 2025
pulisher
Mar 22, 2025

Zevra therapeutics director Bode acquires $79,624 in stock By Investing.com - Investing.com Canada

Mar 22, 2025
pulisher
Mar 21, 2025

Zevra therapeutics director Bode acquires $79,624 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

ZEVRA THERAPEUTICS Director John B Bode Acquires 10,000 Shares - TradingView

Mar 21, 2025
pulisher
Mar 18, 2025

Woodline Partners LP's Strategic Acquisition of Zevra Therapeuti - GuruFocus.com

Mar 18, 2025
pulisher
Mar 17, 2025

Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 17, 2025

HC Wainwright Predicts Lower Earnings for Zevra Therapeutics - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

(ZVRA) On The My Stocks Page - news.stocktradersdaily.com

Mar 16, 2025
pulisher
Mar 15, 2025

Guggenheim Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Zevra Therapeutics (NASDAQ:ZVRA) Earns Overweight Rating from Cantor Fitzgerald - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Roth Capital Predicts Weaker Earnings for Zevra Therapeutics - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 14, 2025
pulisher
Mar 13, 2025

Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga

Mar 13, 2025
pulisher
Mar 13, 2025

Optimistic Buy Rating for Zevra Therapeutics Driven by Miplyffa Launch and Strategic Financial Moves - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Mar 13, 2025
pulisher
Mar 12, 2025

Zevra Therapeutics’ Earnings Call Highlights Success and Growth - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Sector Update: Health Care -March 12, 2025 at 01:43 pm EDT - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Zevra Therapeutics stock target raised to $18 at JMP - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 12, 2025
pulisher
Mar 12, 2025

Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Zevra Therapeutics stock target raised to $18 at JMP By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Buy” by Analysts - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Earnings call transcript: Zevra Therapeutics Q4 2024 reports wider losses By Investing.com - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion Plans - GuruFocus.com

Mar 12, 2025
pulisher
Mar 12, 2025

Zevra Therapeutics: Strong Financial Performance and Strategic Growth Justify Buy Rating - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Zevra Therapeutics: Q4 Earnings Snapshot - The Washington Post

Mar 12, 2025
pulisher
Mar 12, 2025

Zevra Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks

Mar 12, 2025
pulisher
Mar 11, 2025

ZEVRA THERAPEUTICS Earnings Results: $ZVRA Reports Quarterly Earnings - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Earnings call transcript: Zevra Therapeutics Q4 2024 reports wider losses - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Zevra Therapeutics earnings missed by $0.27, revenue topped estimates - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Zevra Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Zevra Earnings: Q4 Revenue Surges to $12M as MIPLYFFA Launch Gains Traction - StockTitan

Mar 11, 2025
pulisher
Mar 10, 2025

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects - Simply Wall St

Mar 10, 2025
pulisher
Mar 09, 2025

Zevra Therapeutics (ZVRA) Expected to Announce Earnings on Tuesday - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Rhumbline Advisers Has $568,000 Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World

Mar 08, 2025

Zevra Therapeutics Inc Stock (ZVRA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):